• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by ANI Pharmaceuticals Inc.

    3/26/26 3:46:27 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ANI Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    00182C103

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    00182C103


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ANI Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    210 Main Street West, Baudette, MN, 56623
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $ANIP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIP

    DatePrice TargetRatingAnalyst
    7/10/2025$84.00Buy
    H.C. Wainwright
    3/14/2025$80.00Buy
    Jefferies
    3/12/2025$85.00Overweight
    Analyst
    12/11/2024$80.00Outperform
    Leerink Partners
    10/11/2024$68.00Overweight
    Piper Sandler
    3/15/2024$80.00Overweight
    CapitalOne
    8/22/2023$60.00 → $73.00Buy
    H.C. Wainwright
    3/1/2023$55.00Buy
    Guggenheim
    More analyst ratings

    $ANIP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    3/8/21 5:11:24 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXYCODONE AND ASPIRIN

    Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

    3/8/21 5:11:06 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for EZETIMIBE AND SIMVASTATIN

    Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

    2/25/21 5:09:42 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on ANI Pharma with a new price target

    H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $84.00

    7/10/25 8:50:19 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on ANI Pharma with a new price target

    Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00

    3/14/25 7:26:09 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on ANI Pharma with a new price target

    Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00

    3/12/25 7:20:36 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ANI Pharmaceuticals Inc.

    SCHEDULE 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    3/26/26 3:46:27 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    3/3/26 7:05:46 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ANI Pharmaceuticals Inc.

    10-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

    2/27/26 6:59:42 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Present at Upcoming Investor Conferences

    PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will present at the following investor conferences: Raymond James & Associates' 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ETLeerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ETBarclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 3:00pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceutica

    2/24/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows: DateFriday, February 27, 2026Time8:00 a.m. ETToll free (U.S.)800-274-8461Conference ID5230834Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section The live and arc

    2/13/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    HEAD OF RARE DISEASE Mutz Christopher sold $226,526 worth of shares (3,162 units at $71.64), decreasing direct ownership by 3% to 91,309 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    3/13/26 5:28:46 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew sold $357,471 worth of shares (4,772 units at $74.91), decreasing direct ownership by 11% to 38,730 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    3/13/26 5:28:48 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $36,310 worth of shares (500 units at $72.62), decreasing direct ownership by 0.63% to 79,390 units (SEC Form 4)

    4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

    3/13/26 5:28:45 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Financials

    Live finance-specific insights

    View All

    ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance

    Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT

    2/27/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows: DateFriday, February 27, 2026Time8:00 a.m. ETToll free (U.S.)800-274-8461Conference ID5230834Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section The live and arc

    2/13/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities

    For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited resultsProvides full year 2026 financial guidance, which includes: Total net revenues of $1,055 million to $1,115 millionCortrophin Gel net revenues of $540 million to $575 millionAdjusted non-GAAP EBITDA of $275 million t

    1/12/26 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Leadership Updates

    Live Leadership Updates

    View All

    Alcami Announces CEO Transition

    Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

    1/13/25 11:12:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

    -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

    8/23/23 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

    9/12/22 6:50:00 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

    SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    11/13/24 4:30:24 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

    SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    3/14/24 7:30:38 AM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

    SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)

    2/13/24 4:58:56 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care